Mito, Japan

Kiyoko Kurosawa

This inventor holds 1 USPTO granted patent. Top assignee: Kaken Co., Ltd.. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kiyoko Kurosawa. Retrieved from https://idiyas.com/inventor/kiyoko-kurosawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kiyoko Kurosawa: Innovator in Radioactive Medicine

Introduction

Kiyoko Kurosawa is a notable inventor based in Mito, Japan. She has made significant contributions to the field of radioactive medicine, particularly through her innovative methods of recovering enriched radioactive technetium.

Latest Patents

Kurosawa holds a patent for a method of recovering enriched radioactive technetium and the system therefor. This patent focuses on utilizing technetium as a raw material for radioactive medicine. The method involves purifying and recovering a very small amount of technetium from a high concentration molybdenum solution with high yield, while avoiding contamination. The process includes generating technetium to a radioactive-equilibrium state and selectively adsorbing it to activated carbon, followed by desorption and purification treatment.

Career Highlights

Kurosawa is associated with Kaken Co., Ltd., where she has been able to apply her expertise in the development of radioactive materials. Her work has been instrumental in advancing the use of technetium in medical applications.

Collaborations

Kurosawa has collaborated with notable coworkers, including Katsuyoshi Tatenuma and Tomomi Ueda. These collaborations have contributed to her innovative approaches in the field.

Conclusion

Kiyoko Kurosawa's work in recovering enriched radioactive technetium showcases her dedication to advancing medical technology. Her contributions are vital for the future of radioactive medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…